Microtubule-Associated Protein Tau: A Marker of Paclitaxel Sensitivity in Breast Cancer

Breast cancers show variable sensitivity to paclitaxel. There is no diagnostic test to identify tumors that are sensitive to this drug. We used U133A chips to identify genes that are associated with pathologic complete response (pCR) to preoperative paclitaxel-containing chemotherapy in stage I-III...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Proceedings of the National Academy of Sciences - PNAS 2005-06, Vol.102 (23), p.8315-8320
Hauptverfasser:	Rouzier, Roman, Rajan, Radhika, Wagner, Peter, Hess, Kenneth R., Gold, David L., Stec, James, Ayers, Mark, Ross, Jeffrey S., Zhang, Peter, Buchholz, Thomas A., Kuerer, Henry, Green, Marjorie, Arun, Banu, Hortobagyi, Gabriel N., Symmans, W. Fraser, Pusztai, Lajos, Einhorn, Lawrence H.
Format:	Artikel
Sprache:	eng
Schlagworte:	Biological Sciences Biomarkers - metabolism Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - metabolism Breast Neoplasms - pathology Cell lines Chemotherapy Cyclophosphamide - pharmacology Down-Regulation Doxorubicin - pharmacology Drug resistance Drug Resistance, Neoplasm - genetics Epirubicin - pharmacology Female Fluorescence Fluorouracil - pharmacology Gene Expression Regulation, Neoplastic Humans Microtubules Microtubules - metabolism Paclitaxel - metabolism Paclitaxel - pharmacology Paclitaxel - therapeutic use Polymerization Proteins Residual neoplasm RNA, Messenger - genetics RNA, Messenger - metabolism Small interfering RNA Tau proteins tau Proteins - genetics tau Proteins - metabolism Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Breast cancers show variable sensitivity to paclitaxel. There is no diagnostic test to identify tumors that are sensitive to this drug. We used U133A chips to identify genes that are associated with pathologic complete response (pCR) to preoperative paclitaxel-containing chemotherapy in stage I-III breast cancer (n = 82). Tau was the most differentially expressed gene. Tumors with pCR had significantly lower ($P
ISSN:	0027-8424 1091-6490
DOI:	10.1073/pnas.0408974102